Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 9OTHER 7NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Astrocytoma 29Central Nervous System Neoplasms 28Unspecified Adult Solid Tumor, Protocol Specific 18Ovarian Neoplasms 17Oligodendroglioma 17Medulloblastoma 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Lung Neoplasms 15Optic Nerve Glioma 14Neuroblastoma 14Lymphoma 14Carcinoma, Non-Small-Cell Lung 14Leukemia 13Glioblastoma 13Familial ependymoma 12Choroid Plexus Neoplasms 12Carcinoma, Ovarian Epithelial 12Fallopian Tube Neoplasms 11Burkitt Lymphoma 11Breast Neoplasms 11Sarcoma 10Colorectal Neoplasms 9Brain Neoplasms 9Recurrence 8Lymphoma, Large B-Cell, Diffuse 8Brenner Tumor 8Lymphoma, Non-Hodgkin 7Glioma 7Colonic Neoplasms 7Uterine Cervical Neoplasms 6

Interventions

Fenretinide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × NETWORK × Leukemia, Neutrophilic, Chronic × Clear all
NCT00104923 2017-07-19

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

California Cancer Consortium

Phase 1 Completed
29 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡